


Target : NapaJen Pharma, Inc.

Outline : A Delivery technology platform of nucleic acids or other materials, and drug-development using the delivery platform

Authorized Investment : USD 9 million (maximum)/USD 12 million (maximum)/USD 12 million (maximum)

Announcement date of investment : February 3, 2014/December 7, 2016/December 25, 2018



- Supports drug discovery/development of academia originated technology
- Anticipates developing nucleic acid drugs that can be administered systemically and address unmet medical needs
- Contributes stimulation of drug-discovery/development venture industry through co-investment with private venture capitals